Premium
A pilot study of 220 mg/m 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity
Author(s) -
Moreau Philippe,
Kergueris MarieFrance,
Milpied NoE¨l,
Le Tortorec Stéphane,
Mahé Béatrice,
Bulabois ClaudeEric,
Rapp MarieJosÉ,
Larousse Claude,
Bataille RÉgis,
Harousseau JeanLuc
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1932.x
Subject(s) - melphalan , mucositis , pharmacokinetics , multiple myeloma , medicine , toxicity , volume of distribution , transplantation , autologous stem cell transplantation , hematopoietic stem cell transplantation , hematologic neoplasms , stem cell , surgery , gastroenterology , pharmacology , biology , genetics
We studied the pharmacokinetics and toxicity of 220 mg/m 2 melphalan (HDM 220) followed by autologous stem cell transplantation in 16 patients with advanced haematological malignancies. Pharmacokinetic parameters (mean values of steady‐state volume of distribution 14.6 l/m 2 , total body clearance 313 ml/min/m 2 , elimination half‐life 46 min) were the same as those of 140 or 200 mg/m 2 melphalan in previous reports. HDM 220 was feasible. Extramedullary toxicity was mainly W.H.O. grade 4 mucositis (13/16 patients). The median duration of 41 d (10, not reached) of thrombocytopenia <25 × 10 9 /l was long. In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.